Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma

Saroj Vadhan-Raj, Nicholas E. Papadopoulos, Michael A. Burgess, Kaye A. Linke, Shreyaskumar R. Patel, Carolyn Hays, Anthony Arcenas, Carl Plager, Andrzej P. Kudelka, Walter N. Hittelman, Hal Broxmeyer, Douglas E. Williams, Leslie Garrison, Robert S. Benjamin

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Purpose: To evaluate the clinical safety and ability of PIXY321, a novel fusion protein of recombinant human granulocyte-macrophage colony- stimulating factor (GM-CSF) and interleukin-3 (IL-3), to ameliorate chemotherapy-induced multilineage myelosuppression. Patients and Methods: PIXY321 was administered by subcutaneous injection twice daily (25 to 1,000 μg/m2/d) over 14 days to 24 chemotherapy-naive patients with sarcoma in a phase I/II study. Three weeks from the initiation of PIXY321, the first cycle of chemotherapy with cyclophosphamide, doxorubicin, and dacarbazine (DTIC) (CyADIC) was administered over 3 days. Four weeks later, a second cycle of CyADIC was administered, followed by 14 days of PIXY321. Results: Treatment with PIXY321 was well tolerated. Local skin reactions and constitutional symptoms were the main side effects. The dose-limiting toxicity was not encountered; however, headache and fatigue were more frequent at the highest dose (1,000 μg/m2). PIXY321 before chemotherapy elicited a modest increase in the WBC count (consisting mainly of mature neutrophils), platelets, and corrected reticulocyte counts (all P <.001). Following chemotherapy, PIXY321 at effective doses (500 to 1,000 μg/m2/d), significantly reduced both the degree (mean nadir, 70 v 310/μL; P = .016) and duration (mean days <500/μL, 6.6 v 3.9 days; P = .002) of neutropenia. Cumulative thrombocytopenia was not observed during the first two cycles of CyADIC (mean nadir platelet count, 103 v 95 x 103/μL, in cycles no. 1 and 2, respectively; P = NS). Compared with our historic control data, the mean nadir platelet count in cycle no. 2 was significantly higher after PIXY321 (1.7-fold, P <.05) than with CyADIC alone or with GM-CSF support. There was a suggestion for a dose response, since the mean percentage change in nadir platelet values from cycle no. 1 to cycle no. 2 increased with the PIXY321 dose (P <.02), with the peak effect observed at 750 μg/m2/d. Conclusion: These results suggest a potential clinical role for PIXY321 in attenuating the cumulative multilineage hematopoietic toxicity of chemotherapy.

Original languageEnglish (US)
Pages (from-to)715-724
Number of pages10
JournalJournal of Clinical Oncology
Volume12
Issue number4
StatePublished - Apr 1994
Externally publishedYes

Fingerprint

Interleukin-3
Granulocyte-Macrophage Colony-Stimulating Factor
Sarcoma
Drug Therapy
Dacarbazine
Proteins
Platelet Count
Blood Platelets
Recombinant Fusion Proteins
Reticulocyte Count
Subcutaneous Injections
Neutropenia
Thrombocytopenia
Doxorubicin
Cyclophosphamide
Fatigue
Headache
Neutrophils
Safety
Skin

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vadhan-Raj, S., Papadopoulos, N. E., Burgess, M. A., Linke, K. A., Patel, S. R., Hays, C., ... Benjamin, R. S. (1994). Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. Journal of Clinical Oncology, 12(4), 715-724.

Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. / Vadhan-Raj, Saroj; Papadopoulos, Nicholas E.; Burgess, Michael A.; Linke, Kaye A.; Patel, Shreyaskumar R.; Hays, Carolyn; Arcenas, Anthony; Plager, Carl; Kudelka, Andrzej P.; Hittelman, Walter N.; Broxmeyer, Hal; Williams, Douglas E.; Garrison, Leslie; Benjamin, Robert S.

In: Journal of Clinical Oncology, Vol. 12, No. 4, 04.1994, p. 715-724.

Research output: Contribution to journalArticle

Vadhan-Raj, S, Papadopoulos, NE, Burgess, MA, Linke, KA, Patel, SR, Hays, C, Arcenas, A, Plager, C, Kudelka, AP, Hittelman, WN, Broxmeyer, H, Williams, DE, Garrison, L & Benjamin, RS 1994, 'Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma', Journal of Clinical Oncology, vol. 12, no. 4, pp. 715-724.
Vadhan-Raj, Saroj ; Papadopoulos, Nicholas E. ; Burgess, Michael A. ; Linke, Kaye A. ; Patel, Shreyaskumar R. ; Hays, Carolyn ; Arcenas, Anthony ; Plager, Carl ; Kudelka, Andrzej P. ; Hittelman, Walter N. ; Broxmeyer, Hal ; Williams, Douglas E. ; Garrison, Leslie ; Benjamin, Robert S. / Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma. In: Journal of Clinical Oncology. 1994 ; Vol. 12, No. 4. pp. 715-724.
@article{a47636404df74937b15046545a67997c,
title = "Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma",
abstract = "Purpose: To evaluate the clinical safety and ability of PIXY321, a novel fusion protein of recombinant human granulocyte-macrophage colony- stimulating factor (GM-CSF) and interleukin-3 (IL-3), to ameliorate chemotherapy-induced multilineage myelosuppression. Patients and Methods: PIXY321 was administered by subcutaneous injection twice daily (25 to 1,000 μg/m2/d) over 14 days to 24 chemotherapy-naive patients with sarcoma in a phase I/II study. Three weeks from the initiation of PIXY321, the first cycle of chemotherapy with cyclophosphamide, doxorubicin, and dacarbazine (DTIC) (CyADIC) was administered over 3 days. Four weeks later, a second cycle of CyADIC was administered, followed by 14 days of PIXY321. Results: Treatment with PIXY321 was well tolerated. Local skin reactions and constitutional symptoms were the main side effects. The dose-limiting toxicity was not encountered; however, headache and fatigue were more frequent at the highest dose (1,000 μg/m2). PIXY321 before chemotherapy elicited a modest increase in the WBC count (consisting mainly of mature neutrophils), platelets, and corrected reticulocyte counts (all P <.001). Following chemotherapy, PIXY321 at effective doses (500 to 1,000 μg/m2/d), significantly reduced both the degree (mean nadir, 70 v 310/μL; P = .016) and duration (mean days <500/μL, 6.6 v 3.9 days; P = .002) of neutropenia. Cumulative thrombocytopenia was not observed during the first two cycles of CyADIC (mean nadir platelet count, 103 v 95 x 103/μL, in cycles no. 1 and 2, respectively; P = NS). Compared with our historic control data, the mean nadir platelet count in cycle no. 2 was significantly higher after PIXY321 (1.7-fold, P <.05) than with CyADIC alone or with GM-CSF support. There was a suggestion for a dose response, since the mean percentage change in nadir platelet values from cycle no. 1 to cycle no. 2 increased with the PIXY321 dose (P <.02), with the peak effect observed at 750 μg/m2/d. Conclusion: These results suggest a potential clinical role for PIXY321 in attenuating the cumulative multilineage hematopoietic toxicity of chemotherapy.",
author = "Saroj Vadhan-Raj and Papadopoulos, {Nicholas E.} and Burgess, {Michael A.} and Linke, {Kaye A.} and Patel, {Shreyaskumar R.} and Carolyn Hays and Anthony Arcenas and Carl Plager and Kudelka, {Andrzej P.} and Hittelman, {Walter N.} and Hal Broxmeyer and Williams, {Douglas E.} and Leslie Garrison and Benjamin, {Robert S.}",
year = "1994",
month = "4",
language = "English (US)",
volume = "12",
pages = "715--724",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma

AU - Vadhan-Raj, Saroj

AU - Papadopoulos, Nicholas E.

AU - Burgess, Michael A.

AU - Linke, Kaye A.

AU - Patel, Shreyaskumar R.

AU - Hays, Carolyn

AU - Arcenas, Anthony

AU - Plager, Carl

AU - Kudelka, Andrzej P.

AU - Hittelman, Walter N.

AU - Broxmeyer, Hal

AU - Williams, Douglas E.

AU - Garrison, Leslie

AU - Benjamin, Robert S.

PY - 1994/4

Y1 - 1994/4

N2 - Purpose: To evaluate the clinical safety and ability of PIXY321, a novel fusion protein of recombinant human granulocyte-macrophage colony- stimulating factor (GM-CSF) and interleukin-3 (IL-3), to ameliorate chemotherapy-induced multilineage myelosuppression. Patients and Methods: PIXY321 was administered by subcutaneous injection twice daily (25 to 1,000 μg/m2/d) over 14 days to 24 chemotherapy-naive patients with sarcoma in a phase I/II study. Three weeks from the initiation of PIXY321, the first cycle of chemotherapy with cyclophosphamide, doxorubicin, and dacarbazine (DTIC) (CyADIC) was administered over 3 days. Four weeks later, a second cycle of CyADIC was administered, followed by 14 days of PIXY321. Results: Treatment with PIXY321 was well tolerated. Local skin reactions and constitutional symptoms were the main side effects. The dose-limiting toxicity was not encountered; however, headache and fatigue were more frequent at the highest dose (1,000 μg/m2). PIXY321 before chemotherapy elicited a modest increase in the WBC count (consisting mainly of mature neutrophils), platelets, and corrected reticulocyte counts (all P <.001). Following chemotherapy, PIXY321 at effective doses (500 to 1,000 μg/m2/d), significantly reduced both the degree (mean nadir, 70 v 310/μL; P = .016) and duration (mean days <500/μL, 6.6 v 3.9 days; P = .002) of neutropenia. Cumulative thrombocytopenia was not observed during the first two cycles of CyADIC (mean nadir platelet count, 103 v 95 x 103/μL, in cycles no. 1 and 2, respectively; P = NS). Compared with our historic control data, the mean nadir platelet count in cycle no. 2 was significantly higher after PIXY321 (1.7-fold, P <.05) than with CyADIC alone or with GM-CSF support. There was a suggestion for a dose response, since the mean percentage change in nadir platelet values from cycle no. 1 to cycle no. 2 increased with the PIXY321 dose (P <.02), with the peak effect observed at 750 μg/m2/d. Conclusion: These results suggest a potential clinical role for PIXY321 in attenuating the cumulative multilineage hematopoietic toxicity of chemotherapy.

AB - Purpose: To evaluate the clinical safety and ability of PIXY321, a novel fusion protein of recombinant human granulocyte-macrophage colony- stimulating factor (GM-CSF) and interleukin-3 (IL-3), to ameliorate chemotherapy-induced multilineage myelosuppression. Patients and Methods: PIXY321 was administered by subcutaneous injection twice daily (25 to 1,000 μg/m2/d) over 14 days to 24 chemotherapy-naive patients with sarcoma in a phase I/II study. Three weeks from the initiation of PIXY321, the first cycle of chemotherapy with cyclophosphamide, doxorubicin, and dacarbazine (DTIC) (CyADIC) was administered over 3 days. Four weeks later, a second cycle of CyADIC was administered, followed by 14 days of PIXY321. Results: Treatment with PIXY321 was well tolerated. Local skin reactions and constitutional symptoms were the main side effects. The dose-limiting toxicity was not encountered; however, headache and fatigue were more frequent at the highest dose (1,000 μg/m2). PIXY321 before chemotherapy elicited a modest increase in the WBC count (consisting mainly of mature neutrophils), platelets, and corrected reticulocyte counts (all P <.001). Following chemotherapy, PIXY321 at effective doses (500 to 1,000 μg/m2/d), significantly reduced both the degree (mean nadir, 70 v 310/μL; P = .016) and duration (mean days <500/μL, 6.6 v 3.9 days; P = .002) of neutropenia. Cumulative thrombocytopenia was not observed during the first two cycles of CyADIC (mean nadir platelet count, 103 v 95 x 103/μL, in cycles no. 1 and 2, respectively; P = NS). Compared with our historic control data, the mean nadir platelet count in cycle no. 2 was significantly higher after PIXY321 (1.7-fold, P <.05) than with CyADIC alone or with GM-CSF support. There was a suggestion for a dose response, since the mean percentage change in nadir platelet values from cycle no. 1 to cycle no. 2 increased with the PIXY321 dose (P <.02), with the peak effect observed at 750 μg/m2/d. Conclusion: These results suggest a potential clinical role for PIXY321 in attenuating the cumulative multilineage hematopoietic toxicity of chemotherapy.

UR - http://www.scopus.com/inward/record.url?scp=0028255994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028255994&partnerID=8YFLogxK

M3 - Article

C2 - 8151315

AN - SCOPUS:0028255994

VL - 12

SP - 715

EP - 724

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -